CLU and Parkinson disease: The calculated α-synuclein-to-clusterin ratio (α-Syn/Clu×1000) had improved overall accuracy, consistently in both training and validation cohorts (98 and 99%, respectively), over α-synuclein alone in discriminating PD from PSP and CBD.